Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
- PMID: 31010049
- PMCID: PMC6514656
- DOI: 10.3390/ijms20081948
Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
Abstract
Nonalcoholic Fatty Liver Disease (NAFLD) represents the leading cause of liver disease in developed countries but its diffusion is currently also emerging in Asian countries, in South America and in other developing countries. It is progressively becoming one of the main diseases responsible for hepatic insufficiency, hepatocarcinoma and the need for orthotopic liver transplantation. NAFLD is linked with metabolic syndrome in a close and bidirectional relationship. To date, NAFLD is a diagnosis of exclusion, and liver biopsy is the gold standard for diagnosis. NAFLD pathogenesis is complex and multifactorial, mainly involving genetic, metabolic and environmental factors. New concepts are constantly arising in the literature promising new diagnostic and therapeutic tools. One of the challenges will be to better characterize not only NAFLD development but overall NAFLD progression, in order to better identify NAFLD patients at higher risk of metabolic, cardiovascular and neoplastic complications. This review analyses NAFLD epidemiology and the different prevalence of the disease in distinct groups, particularly according to sex, age, body mass index, type 2 diabetes and dyslipidemia. Furthermore, the work expands on the pathophysiology of NAFLD, examining multiple-hit pathogenesis and the role of different factors in hepatic steatosis development and progression: genetics, metabolic factors and insulin resistance, diet, adipose tissue, gut microbiota, iron deposits, bile acids and circadian clock. In conclusion, the current available therapies for NAFLD will be discussed.
Keywords: insulin resistance; metabolic syndrome; molecular mechanisms; nonalcoholic fatty liver disease; pathogenesis; steatosis; therapy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.World J Gastroenterol. 2016 Sep 28;22(36):8078-93. doi: 10.3748/wjg.v22.i36.8078. World J Gastroenterol. 2016. PMID: 27688650 Free PMC article. Review.
-
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).Metabolism. 2016 Aug;65(8):1038-48. doi: 10.1016/j.metabol.2015.12.012. Epub 2016 Jan 4. Metabolism. 2016. PMID: 26823198 Review.
-
Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.Life Sci. 2021 Apr 15;271:119220. doi: 10.1016/j.lfs.2021.119220. Epub 2021 Feb 13. Life Sci. 2021. PMID: 33592199 Review.
-
A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?Acta Diabetol. 2019 Apr;56(4):385-396. doi: 10.1007/s00592-018-1266-0. Epub 2018 Dec 5. Acta Diabetol. 2019. PMID: 30519965 Review.
-
Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.Curr Diab Rep. 2015 Jun;15(6):607. doi: 10.1007/s11892-015-0607-4. Curr Diab Rep. 2015. PMID: 25894944 Review.
Cited by
-
Sodium fluorocitrate having inhibitory effect on fatty acid uptake ameliorates high fat diet-induced non-alcoholic fatty liver disease in C57BL/6J mice.Sci Rep. 2019 Nov 28;9(1):17839. doi: 10.1038/s41598-019-54476-5. Sci Rep. 2019. PMID: 31780766 Free PMC article.
-
Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects.J Clin Med. 2019 Jul 19;8(7):1057. doi: 10.3390/jcm8071057. J Clin Med. 2019. PMID: 31330971 Free PMC article.
-
Screening New Blood Indicators for Non-alcoholic Fatty Liver Disease (NAFLD) Diagnosis of Chinese Based on Machine Learning.Front Med (Lausanne). 2022 Jun 9;9:771219. doi: 10.3389/fmed.2022.771219. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35755070 Free PMC article.
-
Network Pharmacology Exploration Reveals Anti-Apoptosis as a Common Therapeutic Mechanism for Non-Alcoholic Fatty Liver Disease Treated with Blueberry Leaf Polyphenols.Nutrients. 2021 Nov 13;13(11):4060. doi: 10.3390/nu13114060. Nutrients. 2021. PMID: 34836315 Free PMC article.
-
Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort.J Am Heart Assoc. 2022 Jan 4;11(1):e022576. doi: 10.1161/JAHA.121.022576. Epub 2021 Dec 20. J Am Heart Assoc. 2022. PMID: 34927450 Free PMC article.
References
-
- European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64:1388–1402. doi: 10.1016/j.jhep.2015.11.004. - DOI - PubMed
-
- Ballestri S., Nascimbeni F., Baldelli E., Marrazzo A., Romagnoli D., Targher G., Lonardo A. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism. 2017;72:57–65. doi: 10.1016/j.metabol.2017.04.003. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical